Awake Craniotomy Language Mapping in Children With Drug-Resistant Epilepsy due to Focal Cortical Dysplasia - 12/06/23
Abstract |
Background |
Language mapping during awake craniotomy can allow for precise resection of epileptogenic lesions, while reducing the risk of damage to eloquent cortex. There are few reports in the literature of language mapping during awake craniotomy in children with epilepsy. Some centers may avoid awake craniotomy in the pediatric age group due to concerns that children are unable to cooperate with such procedures.
Methods |
We reviewed pediatric patients from our center with drug-resistant focal epilepsy who underwent language mapping during awake craniotomy and subsequent resection of the epileptogenic lesion.
Results |
Two patients were identified, both female, aged 17 years and 11 years at the time of surgery. Both patients had frequent and disabling focal seizures despite trials of multiple antiseizure medications. Both patients had resection of their epileptogenic lesions with the aid of intraoperative language mapping; in both cases pathology was consistent with focal cortical dysplasia. Both patients had transient language difficulties in the immediate postoperative period but no deficits at six-month follow-up. Both patients are now seizure-free.
Conclusions |
Awake craniotomy should be considered in pediatric patients with drug-resistant epilepsy in whom the suspected epileptogenic lesion is in close proximity to cortical language areas.
El texto completo de este artículo está disponible en PDF.Keywords : Awake craniotomy, Focal cortical dysplasia, Focal epilepsy, Pediatric
Esquema
| Disclosures: Dr. Myers holds or has held research funding from Savoy Foundation, Dravet Canada, Research Institute of the McGill University Health Centre, Citizens United for Research in Epilepsy (439534), Epilepsy Canada, Koolen-de Vries Foundation, Liam Foundation, and Fonds de Recherches du Québec – Santé; he is also a site principal investigator for studies by LivaNova, Ionis, and Ultragenyx. The other authors report no conflicts of interest. |
|
| Funding: Supported by Research Institute of the McGill University Health Centre and Fonds de Recherches du Québec – Santé. |
|
| Conflicts of interest: Dr. Myers holds or has held research funding from Savoy Foundation, Dravet Canada, Research Institute of the McGill University Health Centre, Citizens United for Research in Epilepsy (439534), Koolen-de Vries Foundation, Liam Foundation, and Fonds de Recherches du Québec – Santé; he is also a site principal investigator for studies by LivaNova, Ultragenyx, and Ionis. The other authors report no conflicts of interest. |
Vol 144
P. 39-43 - juillet 2023 Regresar al número
Artículo precedente
- Normal Outcome With Prenatal Intervention for Riboflavin Transporter Defect
- Natasha Elks, Jo M. Wilmshurst, Sharika V. Raga
- Carbamazepine-Triggered Hemophagocytic Lymphohistiocytosis: A Case Report and Review of Literature
- Prabhjot Kaur, Vinay Munikoty, Vaishnavi Chandramohan
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?